Enalapril — Discount Pricing

Other medications in Heart & Cardiovascular

• Eplerenone
• Epoprostenol
• Eprosartan
• Evolocumab
• Ezetimibe
• Felodipine
• Fenofibrate
• Flecainide

About Enalapril

Enalapril is a widely prescribed medication crucial for managing conditions like high blood pressure and heart failure. It plays a significant role in improving cardiovascular health for countless individuals. At TheDrugClub, we believe essential medications should be accessible and affordable. That's why we're committed to helping our members save significantly on their enalapril prescriptions.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Enalapril is approved for (FDA label)

Enalapril maleate oral solution is an angiotensin-converting enzyme inhibitor indicated for: treatment of hypertension in adults and children older than one month, to lower blood pressure.

Source: Read the full FDA label on DailyMed. Label effective date: March 29, 2019.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Enalapril (FDA label)

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue enalapril maleate as soon as possible [see Warnings and Precautions (5.1) ]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) ]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue enalapril maleate as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: e81a8aca-0e7c-4a02-b596-09e4ac22c70e. SPL document ID: 4f8091c3-1233-48b9-a15e-e5da07c4272c. Label effective date: March 29, 2019. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Enalapril (FDA label)

Enalapril maleate oral solution is a ready-to-use oral solution that contains 1 mg/mL of enalapril maleate. It is a clear, colorless raspberry flavored solution packaged in a 150 mL white, round, high-density polyethylene bottle with a white, polypropylene, child-resistant cap and tamper-evident seal. Each bottle contains 150 mL. Enalapril maleate oral solution is a ready-to-use oral solution: 1 mg/mL enalapril maleate. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: e81a8aca-0e7c-4a02-b596-09e4ac22c70e. SPL document ID: 4f8091c3-1233-48b9-a15e-e5da07c4272c. Label effective date: March 29, 2019. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Enalapril (FDA label)

The following adverse reactions are described elsewhere: Angioedema [see Warnings and Precautions (5.2) ] Hypotension [see Warnings and Precautions (5.3) ] Hepatic failure [see Warnings and Precautions (5.4) ] Renal impairment [see Warnings and Precautions (5.5) ] Hyperkalemia [see Warnings and Precautions (5.6) ] The most common adverse reaction for patients treated for hypertension (≥3%) was fatigue. ( 6.1 ) The most common adverse reactions for patients treated for heart failure (>6%) were hypotension and dizziness. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: e81a8aca-0e7c-4a02-b596-09e4ac22c70e. SPL document ID: 4f8091c3-1233-48b9-a15e-e5da07c4272c. Label effective date: March 29, 2019. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Enalapril (FDA label)

Enalapril maleate is contraindicated in patients with: a history of angioedema or hypersensitivity related to previous treatment with an angiotensin converting enzyme (ACE) inhibitor [see Warnings and Precautions (5.2) ]. hereditary or idiopathic angioedema [see Warnings and Precautions (5.2) ]. Do not co-administer aliskiren with enalapril maleate in patients with diabetes [see Drug Interactions (7.2) ] . Enalapril maleate is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer enalapril maleate within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [see Warnings and Precautions (5.2) ] . Hypersensitivity related to previous treatment with an ACEI. ( 4 ) Hereditary or idiopathic angioedema. ( 4 ) Do not co-administer aliskiren in patients with diabetes. ( 4 ) In combination with a neprilysin inhibitor. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: e81a8aca-0e7c-4a02-b596-09e4ac22c70e. SPL document ID: 4f8091c3-1233-48b9-a15e-e5da07c4272c. Label effective date: March 29, 2019. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Enalapril (FDA label)

Angioedema and Anaphylactoid Reactions. ( 5.2 ) Impaired Renal Function: Assess renal function. ( 5.5 ) Hyperkalemia. ( 5.6 ) 5.1 Fetal Toxicity Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue enalapril maleate as soon as possible [see Use in Specific Populations (8.1) ] . 5.2 Angioedema and Anaphylactoid Reactions Angioedema Head and Neck Angioedema Angioedema of the face, extremities, lips, tongue, glottis and/or larynx, including some fatal reactions, have occurred in patients treated with angiotensin converting enzyme inhibitors, including enalapril maleate, at any time during treatment.

Source: FDA prescribing information (DailyMed). Set ID: e81a8aca-0e7c-4a02-b596-09e4ac22c70e. SPL document ID: 4f8091c3-1233-48b9-a15e-e5da07c4272c. Label effective date: March 29, 2019. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Enalapril (FDA label)

In patients who are elderly, volume-depleted (as on diuretic therapy), or with compromised renal function, use with NSAIDs, including selective COX-2 inhibitors, may result in deterioration of renal function, including renal failure. Monitor renal function periodically. ( 7.1 ) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension and hyperkalemia. ( 7.2 ) Avoid potassium sparing agents in patients with heart failure. ( 7.3 ) Monitor serum lithium levels frequently. ( 7.4 ) 7.1 Non-Steroidal Anti-Inflammatory Agents (NSAIDs) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including enalapril, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving enalapril and NSAID therapy.

Source: FDA prescribing information (DailyMed). Set ID: e81a8aca-0e7c-4a02-b596-09e4ac22c70e. SPL document ID: 4f8091c3-1233-48b9-a15e-e5da07c4272c. Label effective date: March 29, 2019. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.